menu

CDC Recommendations for Pneumococcal Disease in Adults Under Age 65 With Certain Chronic Conditions

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
x
Hello, there.

Indications and Usage 

PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Select Safety Information for PNEUMOVAX 23

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Read full SSI for PNEUMOVAX 23>>
CONTINUE TO PROGRAM

CDC Recommendations for Pneumococcal Disease in Adults Under Age 65 With Certain Chronic Conditions

CDC Recommendations for Pneumococcal Disease in Adults Under Age 65 With Certain Chronic Conditions
RestartResume

Adults with certain chronic conditions are at increased risk for pneumococcal disease. Learn about the CDC pneumococcal vaccination recommendations.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    Did you know the risk for invasive pneumococcal disease is approximately 3- to 7-fold higher in adults younger than 65 who are diagnosed with diabetes, chronic heart disease, or chronic lung disease (COPD) than in age-matched healthy adults?1,a The CDC specifically recommends one dose of PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) at the time of diagnosis for these patients.2

    Here to walk us through the CDC recommendations is Dr. Vincent Hsu, an infectious disease specialist.

    References

    1. Shea KM et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infectious Diseases. 2014 March: 3,5.
    2. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816–819. https://www.cdc.gov/mmwr/pdf/wk/mm6140.pdf.

    aStudy Design: Retrospective cohort study (adults aged-matched 18–64 years) using data from January 1, 2006, through December 31, 2010, from 3 health care claims databases representing >35 million insured adults. Risk for IPD was compared to age matched healthy counterparts.1

    CDC, Centers for Disease Control and Prevention; COPD, chronic obstructive pulmonary disease; IPD, invasive pneumococcal disease.

    Indications and Usage 

    PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

    PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

    PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

    Select Safety Information for PNEUMOVAX 23

    Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

    Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

    Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

    Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

    Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

    PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

    The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

    Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

    Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/22/20